menu
    • menu
    [{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group and Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cyclin A","graph1":"Oncology","graph2":"Discovery","graph3":"Circle Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ The Column Group and Nextech","highestDevelopmentStatusID":"2","companyTruncated":"Circle Pharma \/ The Column Group and Nextech"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CID-078","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Circle Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Circle Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CID-078","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Circle Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Circle Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series D Financing","leadProduct":"CID-078","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Circle Pharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Circle Pharma \/ The Column Group","highestDevelopmentStatusID":"12","companyTruncated":"Circle Pharma \/ The Column Group"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Macrocycle-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Circle Pharma","amount2":0.60999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Circle Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"12","companyTruncated":"Circle Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CID-078","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Circle Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Circle Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Circle Pharma

    Menu

    Circle Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Circle Pharma Doses First Patients in Trial for Oral Cyclin A/B Inhibitor CID-078

                            Details : CID-078 is a cyclin A/B RxL inhibitor. The trial will evaluate it in patients with advanced solid tumors with elevated E2F transcription factor activity, such as lung cancer and breast cancer.

                            Brand Name : CID-078

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 15, 2024

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrocycle-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $607.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boehringer Ingelheim and Circle Pharma Announce Precision Cancer Treatment Pact

                            Details : The collaboration aims to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 09, 2024

                            Lead Product(s) : Macrocycle-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $607.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Column Group

                            Deal Size : $90.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Circle Pharma Closes $90 Million Series D to Advance Oral Macrocycle Therapies

                            Details : The financing aims to fund the clinical development of CID-078, which is being evaluated in the early-stage clinical trial studies for the treatment of Advanced Solid Tumor.

                            Brand Name : CID-078

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 03, 2024

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Column Group

                            Deal Size : $90.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Circle Pharma Files IND for First-in-Class Oral Cyclin A/B RxL Inhibitor for Solid Tumors

                            Details : CID-078 is an orally bioavailable macrocycle and the first of its kind cyclin A/B RxL inhibitor, developed using the company’s proprietary MXMO platform for the treatment of multiple solid tumors.

                            Brand Name : CID-078

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibit...

                            Details : CID-078 is a small molecule orally bioavailable macrocycle with dual cyclin A and B inhibitory activity that drives synthetic lethality in multiple tumor types.

                            Brand Name : CID-078

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2023

                            Lead Product(s) : CID-078

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Circle Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : The Column Group and Nextech

                            Deal Size : $66.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Circle Pharma Raises $66 Million in Series C Financing

                            Details : Proceeds from the financing will be used to advance the Company’s wholly owned cyclin-targeted programs towards the clinic, with potential applications in Rb-dysregulated cancers such as small cell lung cancer and cyclin E dependent malignancies, inclu...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 16, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : The Column Group and Nextech

                            Deal Size : $66.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth